Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bendamustine in Patients with Rituximab-Refractory Indolent and Transformed non-Hodgkin's Lymphoma: Results from a Phase II Multicenter, Single-Agent Study

Bendamustine in Patients with Rituximab-Refractory Indolent and Transformed non-Hodgkin's Lymphoma: Results from a Phase II Multicenter, Single-Agent Study. J Clin Oncol. 2008; 26(2):204-210.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.